George Simeon — SEC insider filings

SEC reporting owner CIK 1595117. 37 insider filings on record with FilingPulse; latest filed 2026-10-16.

Transaction summary — filings shown

Covers all 37 filings on record, filed 2020-09-28 to 2026-10-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Arcellx, Inc. (ACLX)10% owner22 legs · 1,666,667 sh · $25,000,0054 legs · 1,012,833 sh · $45,589,31710
CRISPR Therapeutics AG (CRSP)Director93 legs · 989,812 sh · $51,499,9181 leg · 14,514 sh · $720,37311
Zenas BioPharma, Inc. (ZBIO)10% owner25 legs · 2,361,609 sh · $40,399,983—6
Nkarta, Inc. (NKTX)Director84 legs · 3,333,333 sh · $39,999,995—6
ADARx Pharmaceuticals, Inc. (ADRX)Director, 10% owner23 legs · 1,600,000 sh · $27,200,000—12
Design Therapeutics, Inc. (DSGN)Director, 10% owner84 legs · 1,150,000 sh · $12,574,078—10
Odyssey Therapeutics, Inc. (ODTX)10% owner13 legs · 555,555 sh · $9,999,9903 legs · 1,780 sh · $32,04030
Avalyn Pharma Inc. (AVLN)10% owner12 legs · 555,555 sh · $9,999,990—8
eFFECTOR Therapeutics, Inc. (EFTR)10% owner1—2 legs · 609,163 sh · $369,457—
Principia Biopharma Inc. (PRNB)Director1——5

+1 more issuer among the filings shown — every filing appears in the table below.

Insider filings — George Simeon

FiledFormIssuerReported transactionsSource
2026-10-164CRISPR Therapeutics AG (CRSP)Option exercise (M): 30,000 @ $14 · Sale (S): 14,514 @ $49.63 · Option exercise (M): 30,000 (derivative) @ $0EDGAR
2026-09-294ADARx Pharmaceuticals, Inc. (ADRX)Conversion (C): 3,334,938 · Conversion (C): 1,113,666 · Conversion (C): 512,897 · Purchase (P): 592,593 @ $17 · Conversion (C): 1,538,691 · Purchase (P): 414,814 @ $17 · +9 moreEDGAR
2026-09-243ADARx Pharmaceuticals, Inc. (ADRX)Holdings only — no transactions reportedEDGAR
2026-06-114Nkarta, Inc. (NKTX)Grant/award (A): 37,000 (derivative) @ $0EDGAR
2026-06-114Design Therapeutics, Inc. (DSGN)Grant/award (A): 30,000 (derivative) @ $0EDGAR
2026-06-094CRISPR Therapeutics AG (CRSP)Grant/award (A): 13,000 (derivative) @ $0EDGAR
2026-05-114Odyssey Therapeutics, Inc. (ODTX)
jointly with SR ONE CAPITAL MANAGEMENT, LLC
Conversion (C): 474,048 · Conversion (C): 139,366 · Conversion (C): 59,692 · Conversion (C): 61,762 · Conversion (C): 683,817 · Option exercise/expiry (X): 191,541 · +30 moreEDGAR
2026-05-014Avalyn Pharma Inc. (AVLN)
jointly with SR ONE CAPITAL MANAGEMENT, LLC
Conversion (C): 1,419,298 · Conversion (C): 489,486 · Purchase (P): 277,778 @ $18 · Conversion (C): 354,824 · Conversion (C): 489,486 · Purchase (P): 277,777 @ $18 · +4 moreEDGAR
2025-10-144Zenas BioPharma, Inc. (ZBIO)
jointly with SR ONE CAPITAL MANAGEMENT, LLC
Purchase (P): 63,158 @ $19 · Purchase (P): 63,157 @ $19EDGAR
2025-07-174CRISPR Therapeutics AG (CRSP)Purchase (P): 6,510 @ $52.03 · Purchase (P): 22,319 @ $52.03 · Purchase (P): 960,983 @ $52.03EDGAR
2025-06-124Design Therapeutics, Inc. (DSGN)Grant/award (A): 19,000 (derivative) @ $0EDGAR
2025-06-094Nkarta, Inc. (NKTX)Grant/award (A): 46,000 (derivative) @ $0EDGAR
2025-06-064CRISPR Therapeutics AG (CRSP)Grant/award (A): 13,000 (derivative) @ $0EDGAR
2024-09-164Zenas BioPharma, Inc. (ZBIO)
jointly with SR ONE CAPITAL MANAGEMENT, LLC
Conversion (C): 1,505,388 · Purchase (P): 441,176 @ $17 · Conversion (C): 501,796 · Purchase (P): 1,352,942 @ $17 · Conversion (C): 669,061 · Purchase (P): 441,176 @ $17 · +3 moreEDGAR
2024-06-174Design Therapeutics, Inc. (DSGN)Grant/award (A): 19,000 (derivative) @ $0EDGAR
2024-06-144Nkarta, Inc. (NKTX)Grant/award (A): 22,500 (derivative) @ $0EDGAR
2024-05-314CRISPR Therapeutics AG (CRSP)Grant/award (A): 13,000 (derivative) @ $0EDGAR
2024-03-284Nkarta, Inc. (NKTX)Purchase (P): 1,548,341 @ $10 · Purchase (P): 451,659 @ $10EDGAR
2024-02-274CRISPR Therapeutics AG (CRSP)Grant/award (A): 63,177 @ $71.50 · Grant/award (A): 216,578 @ $71.50 · Grant/award (A): 769,196 @ $71.50EDGAR
2023-11-294eFFECTOR Therapeutics, Inc. (EFTR)
jointly with SR ONE CAPITAL MANAGEMENT, LLC, SR One Capital Fund I Aggregator LP, SR ONE CAPITAL PARTNERS I, LP, SR One Co-Invest I, LLC, SR One Co-Invest I Manager, LLC
Sale (S): 430,578 @ $0.61 · Sale (S): 178,585 @ $0.61EDGAR
2023-06-094Nkarta, Inc. (NKTK)Grant/award (A): 22,500 (derivative) @ $0EDGAR
2023-06-094CRISPR Therapeutics AG (CRSP)Grant/award (A): 13,000 (derivative) @ $0EDGAR
2023-06-024Design Therapeutics, Inc. (DSGN)Grant/award (A): 15,000 (derivative) @ $0EDGAR
2023-05-154Arcellx, Inc. (ACLX)
jointly with SR ONE CAPITAL MANAGEMENT, LLC, SR One Capital Fund I Aggregator LP, SR ONE CAPITAL PARTNERS I, LP, SR One Co-Invest II, LLC, SR One Co-Invest II Manager, LLC
Sale (S): 631,932 @ $45 · Sale (S): 370,612 @ $45 · Sale (S): 6,485 @ $46.15 · Sale (S): 3,804 @ $46.15EDGAR
2022-12-204Design Therapeutics, Inc. (DSGN)Purchase (P): 500,000 @ $8.28 · Purchase (P): 360,000 @ $8.63 · Purchase (P): 40,000 @ $8.14EDGAR
2022-08-174Turning Point Therapeutics, Inc. (TPTX)Disposition to issuer (D): 2,253,660 @ $76 · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 8,500 (derivative) · Disposition to issuer (D): 8,500 (derivative)EDGAR
2022-06-164Design Therapeutics, Inc. (DSGN)Grant/award (A): 15,000 (derivative) @ $0EDGAR
2022-06-104Nkarta, Inc. (NKTX)Grant/award (A): 16,000 (derivative) @ $0EDGAR
2022-06-104CRISPR Therapeutics AG (CRSP)Grant/award (A): 12,000 (derivative) @ $0EDGAR
2022-04-294Nkarta, Inc. (NKTX)Purchase (P): 666,667 @ $15 · Purchase (P): 666,666 @ $15EDGAR
2022-02-104Arcellx, Inc. (ACLX)
jointly with SR ONE CAPITAL MANAGEMENT, LLC, SR ONE CAPITAL PARTNERS I, LP, SR One Capital Fund I Aggregator LP, SR One Co-Invest II, LLC, SR One Co-Invest II Manager, LLC
Conversion (C): 1,550,309 · Conversion (C): 666,651 · Conversion (C): 533,389 · Conversion (C): 649,795 · Purchase (P): 66,667 @ $15 · Conversion (C): 433,196 · +6 moreEDGAR
2021-06-154Nkarta, Inc. (NKTX)Grant/award (A): 16,511 (derivative) @ $0EDGAR
2021-06-144CRISPR Therapeutics AG (CRSP)Grant/award (A): 10,000 (derivative) @ $0EDGAR
2021-06-044Turning Point Therapeutics, Inc. (TPTX)Grant/award (A): 8,500 (derivative) @ $0EDGAR
2021-04-014Design Therapeutics, Inc. (DSGN)Conversion (C): 4,439,839 · Conversion (C): 936,637 · Purchase (P): 250,000 @ $20 · Conversion (C): 7,236,938 (derivative) @ $0 · Conversion (C): 1,526,718 (derivative) @ $0EDGAR
2021-03-294Design Therapeutics, Inc. (DSGN)Grant/award (A): 15,000 (derivative) @ $0EDGAR
2020-09-284Principia Biopharma Inc. (PRNB)Code (U): 2,982,855 @ $100 · Disposition to issuer (D): 28,623 (derivative) · Disposition to issuer (D): 20,475 (derivative) · Disposition to issuer (D): 10,240 (derivative) · Disposition to issuer (D): 10,240 (derivative)EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1595117 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs